COMPARISON OF DIFFERENT COMBINATION CHEMOTHERAPY REGIMENS IN CHILDREN WITH ALL

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is no longer recruiting patients. (Clinical trial summary from the National Cancer Institute's PDQ¿ database) Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving more than one drug may kill more cancer cells. It is not yet known which combination chemotherapy regimen is more effective in treating childhood acute lymphoblastic leukemia. This randomized Phase III trial is comparing different combination chemotherapy regimens to see how well they work in treating children with acute lymphoblastic leukemia.Patients will receive standard combination chemotherapy for 8 weeks. Patients will then be randomly assigned to one of four regimens for additional chemotherapy. Treatment may continue for up to 3 years. Some patients may also undergo radiation therapy. Patients will receive follow-up evaluations every 4-8 weeks for 1 year, every 3 months for 1 year, every 6 months for 1 year, and once a year thereafter.